Your cart is currently empty!
mAb anti-Human MCP-3, 113, Tracer (Biotin Labeled)
Mouse monoclonal antibody to human Macrophage/Monocyte Chemotactic Protein-3 (MCP-3), Tracer (Biotin Labeled), Clone 113, 0.1 mL
Description
Description: Biotin conjugated mouse monoclonal antibody to human macrophage/monocyte chemotactic protein-3 (MCP-3)
Purification: Protein G affinity purified
Product Type: Tracer antibody in matched antibody pair, biotin conjugated.
Target Protein: Human MCP-3
Immunogen: Recombinant human MCP-3 (M.W. 8.5kDa containing 76 amino acids residues)
Fusion Myeloma: Sp2/0-Ag14
Specificity: Reactive with natural and recombinant human MCP-3
Species Reactivity: Human, others not tested.
Cross-reactivity: Does not show any cross reaction with other human cytokines or growth factors tested such as IL-1β, IL-8, MCAF, SAA and EGF.
Host / Isotype: Mouse, IgG1 Kappa
Storage Buffer Formulation: 0.01M PBS, pH 7.0 ± 0.1 in 1% gelatin and 0.1% proclin-300.
Storage: Store at -20oC. Avoid repeated freeze and thaw cycles.
Research Area: Cytokine, chemotaxis
Background:
Macrophage/monocyte chemotactic protein-3 (MCP-3), like other two closely related chemokines (MCP1 and MCP-2), is chemotactic to monocytes, but not to neutrophils. MCP-3 showed 78% sequence homology with MCP-1 and 58% sequence homology with MCP-2. The primary receptor for MCP-3 is D6. MCP-3 also competes with MCP-1 to bind toCCR10, and competes with Rantes and MIP-1α to bind toCCR1.
MCP-3 stimulates macrophage to secrete proteases. A variety of cancer cell lines express MCP-3, suggesting a role in tumor invasion and metastasia.
Applications:
ELISA: In combination with capture antibody clone 542 (Cat. No.: MO-C40088G) and avidin-HRP conjugate, this biotin conjugated antibody can be used as a tracer antibody for human MCP-3 detection.
References:
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
Reviews
There are no reviews yet.